What was the market valuation of the US dry eye-syndrome market in 2024?

The market valuation was $1085.7 Million in 2024. Read More

What is the projected market valuation for the US dry eye-syndrome market in 2035?

The projected valuation for 2035 is $1922.55 Million. Read More

What is the expected CAGR for the US dry eye-syndrome market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period is 5.33%. Read More

Which segment had the highest valuation in the US dry eye-syndrome market in 2024?

The segment of Artificial Tears had a valuation ranging from $300.0 Million to $550.0 Million. Read More

What are the primary causes of dry eye syndrome identified in the market?

The primary causes include Aging, Medication Induced, Environmental Factors, and Medical Conditions. Read More

Which distribution channel is projected to perform best in the US dry eye-syndrome market?

Retail Pharmacy is projected to perform best, with a valuation range of $400.0 Million to $700.0 Million. Read More

What role do key players like Allergan and Novartis play in the US dry eye-syndrome market?

Key players such as Allergan and Novartis are instrumental in driving innovation and market growth. Read More

How does the end-user segment of Ophthalmology Clinics compare to others in 2024?

Ophthalmology Clinics had a valuation range of $450.0 Million to $800.0 Million, indicating strong demand. Read More

What is the valuation range for Anti-Inflammatory Drugs in the US dry eye-syndrome market?

The valuation range for Anti-Inflammatory Drugs was between $250.0 Million and $450.0 Million. Read More

What trends are expected to shape the US dry eye-syndrome market in the coming years?

Trends may include increased awareness of dry eye syndrome and advancements in treatment options. Read More

US Dry Eye Syndrome Market

US Dry Eye Syndrome Market Research Report: Size, Share, Trend Analysis By Product Type (Artificial Tears, Anti-Inflammatory Drugs, Punctal Plugs, Surgical Devices), By Cause of Dry Eye Syndrome (Aging, Medication Induced, Environmental Factors, Medical Conditions), By Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, Specialty Clinics) and By End Users (Hospitals, Ophthalmology Clinics, Home Care) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.33%

2024 Market Size

$ 1,085.7 Million

2035 Market Size

$ 1,922.55 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/14229-HCR | Pages: 100 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Artificial Tears
  2. 4.1.2 Anti-Inflammatory Drugs
  3. 4.1.3 Punctal Plugs
  4. 4.1.4 Surgical Devices
2. 4.2 Construction, BY Cause of Dry Eye Syndrome (USD Million)
  1. 4.2.1 Aging
  2. 4.2.2 Medication Induced
  3. 4.2.3 Environmental Factors
  4. 4.2.4 Medical Conditions
3. 4.3 Construction, BY Distribution Channel (USD Million)
  1. 4.3.1 Online Pharmacy
  2. 4.3.2 Retail Pharmacy
  3. 4.3.3 Hospital Pharmacy
  4. 4.3.4 Specialty Clinics
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Ophthalmology Clinics
  3. 4.4.3 Home Care
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Santen Pharmaceutical (JP)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bausch Health (CA)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Otsuka Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Hyaluronic Acid (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Johnson & Johnson (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eyevance Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY CAUSE OF DRY EYE SYNDROME
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY CAUSE OF DRY EYE SYNDROME, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY CAUSE OF DRY EYE SYNDROME, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY CAUSE OF DRY EYE SYNDROME, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Dry Eye Syndrome Market Segmentation

US Dry Eye Syndrome Market By Type (USD Million, 2025-2035)

Artificial Tears
Anti-Inflammatory Drugs
Punctal Plugs
Surgical Devices

US Dry Eye Syndrome Market By Cause of Dry Eye Syndrome (USD Million, 2025-2035)

Aging
Medication Induced
Environmental Factors
Medical Conditions

US Dry Eye Syndrome Market By Distribution Channel (USD Million, 2025-2035)

Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Specialty Clinics

US Dry Eye Syndrome Market By End User (USD Million, 2025-2035)

Hospitals
Ophthalmology Clinics
Home Care

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”